ArticleMetabolic brain disease2026
Tu-Si-Zi-Wan reduces D-galactose-induced hepatic and cerebral oxidative damage in aging mice via the Nrf2/ARE pathway.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global aging population necessitates safe, multi-target strategies to combat age-related functional decline. Tu-Si-Zi-Wan (TSZW), a classical medicinal-dietary formula documented in ancient Chinese medical texts and composed of Cuscuta chinensis and Dioscorea opposita, demonstrates multitargeted potential, yet its systemic antiaging mechanisms remain unclear. This study investigated the protective effects of TSZW on hepatic and neurological aging through the Nrf2/ARE pathway while exploring its systemic impact on metabolic and immune homeostasis. Firstly, network pharmacology predicted the targets and pathways of TSZW, identifying 113 shared TSZW-aging targets, with Nrf2, IL-6, and HIF-1α as core nodes enriched in oxidative stress-related pathways. Secondly, a D-galactose-induced aging mouse model was established, followed by 4 months of TSZW intervention (low, medium, and high doses). Behavioral tests (open field, novel object recognition, and grip strength), metabolic and inflammatory marker detection, histopathology, and molecular analyses (western blot, quantitative PCR, and immunofluorescence) were used to assess systemic aging phenotypes, oxidative damage, and Nrf2/ARE pathway activity. TSZW dose-dependently improved motor activity, cognition, and muscle strength; restored liver/kidney function (ALT, AST, Cr, and urea); reduced the serum levels of tumor necrosis factor-α, interleukin 6, and interleukin-1β; and attenuated hepatic/neuronal damage. It suppressed the expression of senescence markers (p16, p21, and p53) while increasing the expression of antioxidant enzymes (SOD and GSH-Px) and reducing oxidative damage (MDA and ROS). Mechanistically, TSZW promoted Nrf2 nuclear translocation; upregulated Hmox1, Nqo1, and Gclm expression; and inhibited Keap1. Notably, high-dose TSZW outperformed vitamin E in reversing immune organ atrophy (thymus and spleen indices) and preserving hippocampal neurons. Collectively, TSZW alleviates hepatic and neurological aging via Nrf2/ARE-mediated antioxidant signaling, with concurrent mitigation of systemic aging phenotypes, including immune organ atrophy and chronic inflammation. Its multicomponent synergy highlights Traditional Chinese medicinal cuisine's potential for systemic anti-aging intervention by targeting oxidative stress-inflammation-metabolic signaling crosstalk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.